CA-BELKIN

4.1.2023 15:01:52 CET | Business Wire | Press release

Belkin celebrates 40 years of industry leadership by introducing a more responsible way to build products

Belkin, a global consumer electronics leader, after two years of development, today introduces a new product material refresh for its top selling mobile power products. Several of Belkin’s most popular wireless chargers, power banks, wall chargers, and car chargers will receive updated product housing materials that consist of 73-75% post-consumer recycled plastics (PCR) and plastic-free packaging. The product transition will be rolled out beginning 2023 and will save an estimated 7,000 metric tons of carbon emissions¹ and reduce CO2-eq emissions for these products by up to 67%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005370/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

The company celebrates 40 years as a market leader and innovator by honoring its deeply rooted commitment to sustainability. Belkin is already on its way to becoming 100% carbon neutral in scope 1 & 2 emissions by 2025. Its commitment to reviewing all areas of the business has included a focus on reducing single-use plastics in packaging which has seen up to a 90% reduction in plastic usage in some products. Today’s announcement addresses Belkin’s approach to reducing its scope 3 emissions.

Belkin made a deliberate and methodical decision to transition product materials to PCR. This takes plastic waste from consumers and repurposes it to create new products. It utilizes plastic that is destined for landfill, giving it new life, while taking meaningful steps to support the circular economy by reducing dependence on virgin plastics. The Life Cycle Assessment conducted by the company shows that utilizing PCR material has a significant reduction in environmental impact.

There are other plastic alternatives in the industry such as:

Recycled plastic (PIR), a method that reuses plastic materials collected at a factory during mass production
Bioplastics, which uses materials from renewable feedstocks such as plants and woodchips
Ocean plastics, which reuses plastic waste collected from the ocean

“When we think about the difference a company of our size and influence can make on the planet, moving away from using virgin plastics in our products is an obvious decision,” said Steve Malony, CEO, Belkin. “I am proud to work alongside the teams that made this shared vision a reality. Their dedication to doing the right thing inspires me and together, we will continue to work towards a more sustainable future.”

The following products will be the first to ship with the new PCR material throughout 2023:

From an aesthetic, quality and engineering perspective, there will be little difference between existing Belkin products and Belkin PCR products. Consumers will be able to decipher the new PCR products by clear callouts on the packaging and product pages online such as: “Made with Recycled Plastic Products” and “100% Plastic Free Packaging.”

Belkin’s engineering and product development teams are based in Los Angeles, Hong Kong, Shenzhen, Vietnam and Taiwan, and work tirelessly to develop innovation that changes the way people connect with their technology while reducing impact on the planet. Belkin takes quality seriously, and nothing enters the market until rigorous testing and approval processes take place. For this new PCR portfolio, Belkin additionally continues to explore new solutions and to conscientiously verify the science behind how Belkin can further reduce its impact on the planet while not compromising on quality. PCR material was sourced from reputable resin vendors and selected and tested by Belkin’s design assurance team.

To learn more about Belkin Sustainability, visit: https://www.belkin.com/company/sustainability/

Press kit can be found here.

About Belkin

Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people to get more life out of every single day whether at home, at work or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remain forever inspired by people and the planet we live on.

¹ Based on forecasted calculations from May 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005370/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom